mexiletine (Namuscla) not recommended for use within NHSScotland

The SMC has rejected mexiletine for symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders. The Committee concluded that the submitting company’s justification of treatment costs in relation to its health benefits was not sufficient to gain acceptance.


Scottish Medicines Consortium